Description
| Method: | CLIA |
| Comment: | |
| Price: | 2000.00 |
| Report: | Daily |
| Usage: | N-terminal precursor of brain natriuretic peptide (NT-proBNP) are released from myocardial cells in response to volume expansion and increased wall tension. They are well established rule-out tools for cardiac disease in unselected communities. NT-proBNP value <125 pg/mL excludes cardiac dysfunction with a high level of certainty in patients presenting with dyspnea. As the value increases heart failure becomes more likely. NT-proBNP levels are correlated with New York Heart Association (NYHA) functional classes for CHF. However, the role of natriuretic peptides extends beyond heart failure diagnosis; it is a clinical support tool in risk stratification & management in both inpatient and outpatient settings. Recent studies have shown that it can also be used for Cardiovascular risk assessment in asymptomatic patients with Type 2 Diabetes Mellitus. |
| Doctor Specialty: | Cardiologist |
| Disease: | Heart Diseases |
| Components: | |
| Courier Charges: | 0.00 |
| Home Collection: | Available |
| Department: | |
| Pre Test Information: | No special preparation required |
